Form 4 for ACRS Aclaris Therapeutics, Inc.
Accepted 2023-02-03 00:00:00 ET · period of report 2023-02-01 · accession 0001209191-23-006999 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-03 | 2023-02-01 | ACRS | Loerop James | Chief Business Off | M - OptEx | — | +11.2K | 11.2K | New | — |
| D | 2023-02-03 | 2023-02-01 | ACRS | Loerop James | Chief Business Off | M - OptEx | $0.00 | -11.2K | 33.8K | -25% | $0 |
| DM | 2023-02-03 | 2023-02-01 | ACRS | Loerop James | Chief Business Off | A - Grant | $0.00 | +135.0K | 105.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-01 | M | A | 11,250 | — | 11,250 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 2 | Derivative | Restricted Stock Units | 2023-02-01 | M | D | 11,250 | $0.00 | 33,750 | D | — · — to — | 11,250 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F4) The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. |
| 3 | Derivative | Restricted Stock Units | 2023-02-01 | A | A | 30,000 | $0.00 | 30,000 | D | — · — to — | 30,000 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F3) The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. |
| 4 | Derivative | Employee Stock Option (Right to Buy) | 2023-02-01 | A | A | 105,000 | $0.00 | 105,000 | D | $16.97 · — to 2033-01-31 | 105,000 Common Stock | (F2) Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. |